Formulex Pharma Innovations

Company Overview

Snapshot

Founded in July 2001, Formulex Pharma Innovations operates with 1–10 employees. The company has raised $55 million across two funding rounds. In June 2010, Dr. Amir Zalcenstein, MBA, was appointed CEO of SoluBest, the predecessor to Formulex Pharma Innovations, signaling a leadership transition for the nanotechnology-based drug delivery firm.

Business overview

Formulex Pharma Innovations specializes in nanotechnology-based drug delivery and formulation, continuing the work of SoluBest Ltd. The company develops innovative formulation solutions for biopharmaceuticals, nutraceuticals, and agrochemicals, serving Israeli and global clients. Utilizing its patented Solumer technology, which maximizes solubility, bioavailability, and physical stability through sub-micron-particle engineering, Formulex designs solid dispersion formulations via a proprietary spray-drying process. The company's technology is proven in preclinical and clinical trials to enhance drug substance performance, and it develops and produces oral, topical, and inhaled dosage forms under GMP conditions for clinical phases one and two.

Strategic signal

The appointment of Dr. Amir Zalcenstein as CEO of SoluBest in June 2010 marked a significant leadership transition for the company, which later became Formulex Pharma Innovations. This move indicated a strategic focus on advancing its nanotechnology-based drug delivery and formulation capabilities, signaling to investors a commitment to experienced leadership in the health tech and life sciences sector.

Company Intelligence Q&A

What is Formulex Pharma Innovations' primary focus?

Formulex Pharma Innovations focuses on nanotechnology-based drug delivery and formulation, developing innovative solutions for biopharmaceuticals, nutraceuticals, and agrochemicals.

When was Formulex Pharma Innovations founded?

Formulex Pharma Innovations was founded in July 2001.

What is the total capital raised by Formulex Pharma Innovations?

Formulex Pharma Innovations has raised $55 million across two funding rounds.

What is the Solumer technology?

Solumer is a patented technology developed by Formulex Pharma Innovations (formerly SoluBest) to maximize the solubility, bioavailability, and physical stability of drug substances using sub-micron-particle engineering and a proprietary spray-drying process.

What significant leadership change occurred in June 2010?

In June 2010, Dr. Amir Zalcenstein, MBA, was appointed CEO of SoluBest, the predecessor to Formulex Pharma Innovations.